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Abstract
Hepatitis C virus (HCV) is hepatotropic and only infects humans and chimpanzees. Consequently, an immunocompetent
small animal model is lacking. The restricted tropism of HCV likely reflects specific host factor requirements. We investigated
if dominant restriction factors expressed in non-liver or non-human cell lines inhibit HCV propagation thus rendering these
cells non-permissive. To this end we explored if HCV completes its replication cycle in heterokaryons between human liver
cell lines and non-permissive cell lines from human non-liver or mouse liver origin. Despite functional viral pattern
recognition pathways and responsiveness to interferon, virus production was observed in all fused cells and was only
ablated when cells were treated with exogenous interferon. These results exclude that constitutive or virus-induced
expression of dominant restriction factors prevents propagation of HCV in these cell types, which has important
implications for HCV tissue and species tropism. In turn, these data strongly advocate transgenic approaches of crucial
human HCV cofactors to establish an immunocompetent small animal model.
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Introduction
HCV is an enveloped virus that at present chronically infects
about 130 million people worldwide [1]. It possesses a positive
strand RNA genome of about 9.6 kb composed of non-translated
regions (NTRs) at the 59and 39 termini required for translation
and RNA replication and a single open reading frame encoding a
large polyprotein [2]. One hallmark of HCV is its high degree of
sequence variability which likely contributes to its ability to
establish chronic infections. Different patient isolates are grouped
into 6 major genotypes and more than 100 subtypes within the
genus Hepacivirinae of the family Flaviviridae [3]. Persistent infection
is associated with a variable degree of liver damage often
progressing in severity over the course of decades. Accordingly,
a large number of patients are at risk of severe sequelae including
life threatening conditions like cirrhosis and hepatocellular
carcinoma [4]. The best available treatment, a combination of
polyethylene glycol (PEG)-conjugated interferon alpha (IFN-a)
and ribavirin, is effective in only a fraction of patients and
associated with severe side effects [5]. A prophylactic or
therapeutic vaccine is not available.
HCV displays a distinct and narrow tissue and host species
tropism and naturally infects only humans and chimpanzees. The
latter therefore are the only reliable immunocompetent animal
model. However, their use is limited due to ethical reasons, high
costs and restricted availability [6]. Transgenic mice containing
human liver xenografts have been described and are permissive for
HCV infection [7], and summarized in [8]. However, these
animals are immunodeficient and hence cannot be used to analyze
HCV pathogenesis and immune control or for vaccine develop-
ment [9].
The mechanisms underlying the restricted tropism of HCV are
poorly characterized and likely reflect specific host factor
requirements for viral entry, RNA replication, assembly and
release. It has been shown that two of the four HCV receptors,
namely CD81 and occludin (OCLN) are used in a highly species-
specific manner and that the rodent orthologs limit viral entry
[10,11]. Furthermore, mouse scavenger receptor class B type I
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support HCV infection with slightly lower efficiency compared to
their human orthologs [12,13]. Importantly, ectopic expression of
all four human entry factors or a combination of mouse SR-BI and
CLDN1 with human CD81 and OCLN rendered non-human cell
lines permissive for HCV cell entry in tissue culture [10].
Moreover, very recently HCV was adapted in tissue culture to
efficiently utilize mouse CD81 as receptor which permitted viral
entry into mouse cells in the absence of human entry factors [14].
Together, these results indicate that transgenesis or viral
adaptation may be sufficient to overcome the barrier to HCV
cell entry also in vivo.
HCV RNA replication has been observed in human non-
hepatic and murine cell lines. However, the efficiency was very low
and required long-term selection procedures using HCV replicon
constructs expressing dominant antibiotic-selectable markers
[15,16,17,18,19]. Furthermore, assembly and release of new
progeny viruses has so far only been described in cells of human
liver origin and was not observed in mouse cells [20]. Presently, it
is not clear if low replication efficiency and lack of virus production
in these cell types are caused by the absence of crucial viral
cofactors, by genetic incompatibility of essential host factors or
alternatively by expression of dominant restriction factors
interfering with replication and virus production in these cells.
Notably, a number of host-encoded restriction factors which
protect mammalian cells from viral infections, particularly by
retroviruses, have been recognized [21,22]. Well characterized
examples are APOBEC3G [23], TRIM5-a proteins [24], and
tetherin [25] that inhibit human immunodeficiency virus 1 (HIV-1)
propagation at various steps of its replication cycle. In case of HCV,
EWI-2wint, a CD81-binding protein, impedes HCV entry by
competing with the viral glycoproteins for interaction with CD81 in
several non-hepatic cells [26]. Moreover, VAP-C which is highly
expressed in various non-hepatic tissues but was not detected in
human liver from chronically infected HCV patients negatively
regulates HCV RNA replication thus possibly contributing to the
hepatotropism of HCV [27].
Given these findings, we developed trans-complementation
systems to investigate if constitutive or virus-induced expression
of dominant restriction factors precludes HCV propagation in
human non-hepatic tissues or non-human liver cells.
Results
Inefficient replication and virus production in human
non-hepatic and mouse liver cell lines
Given previous reports that HCV replication is inefficient in
human non-liver and mouse liver cells and that virus production
does not occur, we first quantitatively assessed the extent of HCV
RNA replication and virus production in a number of cell lines of
human non-liver origin and in mouse liver cell lines. To this end,
we transfected 293T (human embryonic kidney), HeLa (human
cervix carcinoma), and the mouse liver cell lines Hep56.1D,
AML12, and Hepa1-6 with Luc-Jc1 RNA, a highly efficient
genotype 2a chimeric genome containing a luciferase reporter
gene [28]. Human liver cell lines Huh-7.5 [29] and HuH6 [30]
were transfected as reference. Transient viral RNA replication was
monitored by quantification of luciferase activity between 4 and 72
h post transfection (Figure 1A). A non-replicative mutant genome
with a deletion of the conserved GDD motif within the NS5B
RNA dependent RNA polymerase (DGDD) was used as control.
In parallel we quantified production of infectious virions by
inoculation of the highly permissive human hepatoma cell line
Huh-7.5 with the culture fluid of the transfected cells and
subsequent determination of luciferase activity (Figure 1B). When
we transfected Huh-7.5 cells with Luc-Jc1, luciferase activity rose
to more than 10
7 relative light units (RLU) per well at 48 h
surpassing reporter activity measured in DGDD-transfected cells
by more than three orders of magnitude. Similarly, transfection of
HuH6 cell yielded high luciferase activity 72 h post transfection,
thus confirming highly efficient RNA replication of this HCV
genome in these human liver cell lines. In contrast, luciferase
activity in transfected human non-liver and non-human cells was
indistinguishable between replication-competent Luc-Jc1 and the
DGDD mutant suggesting that RNA replication did not occur or
was too inefficient for detection by this assay. Of note, reporter
gene activity 4 h post transfection was lower in these latter cell
lines compared to Huh-7.5 and HuH6 cells indicating that either
transfection efficiency had been poor or that RNA translation was
low in these cells. However, when delivering the viral RNA by
lipofection rather than electroporation we reached comparable
levels of luciferase activity between all cell lines and more than
1,000-fold above the background at 4 h post transfection.
Nevertheless, at subsequent time points post transfection there
was again no difference between Luc-Jc1 and DGDD (data not
shown), thus excluding that merely low transfection or translation
efficiency was responsible for absent or inefficient RNA replica-
tion. Release of infectious particles was only observed from Huh-
7.5 and HuH6 cells transfected with Luc-Jc1, but not from the
other cell lines tested (Figure 1B). Collectively, these results are in
line with previous observations of a limited HCV RNA replication
efficiency in human non-hepatic and mouse liver cell lines.
Efficient trans-complementation of HCV assembly and
release in heterokaryons between human liver cell lines
To explore if one or more steps of the HCV life cycle are
inhibited by expression of host factors that dominantly restrict
HCV, we first developed a system to measure dominant
restrictions of HCV assembly and release. To this end Huh-7.5
Author Summary
The barriers preventing viral transmission across species
are only incompletely understood. On one hand, narrow
tropism reflects dependence of viruses on host cell factors
and their species-specific utilization. On the other hand,
host cellular antiviral factors can preclude virus replication.
These may be constitutively expressed or induced by
interferon triggered upon viral infection. Although viruses
have evolved strategies to cope with these ‘‘restriction
factors’’ in their natural hosts, these mechanisms often fail
in alternative host species. Consequently, restriction
factors pose an important barrier to cross-species viral
transmission. We investigated if virus-induced or constitu-
tively expressed dominant restriction factors preclude HCV
propagation in non-liver tissue and in non-human cells.
Using cell fusions between human and mouse cells we
show that HCV completes its replication cycle in these
heterokaryons. Moreover, we show that the mouse cells
analyzed by us are able to sense viral infection and to
respond to exogenous interferon. These results rule out
that constitutive or virus-induced dominant restriction
factors preclude HCV propagation in these cells. These
findings have implications for HCV tissue and species
tropism and they raise hopes for development of
immunocompetent small models for HCV by transgenesis
of essential human factors and without manipulation of
innate immune mechanisms.
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JFH1 replicon carrying a luciferase reporter gene but lacking the
essential viral assembly factors core, E1, E2, p7 and NS2.
Subsequently, these cells were co-cultured with Huh-7.5 packaging
cells constitutively expressing the aforementioned viral proteins
[31]. After induction of cell fusion between these cell types by
PEG, trans-complementation between replicon and constitutively
expressed viral proteins should selectively restore virus production
in heterokaryons resulting from fusion of replicon with packaging
cells (Figure 2A). Heterokaryon formation was monitored by co-
localization of NS5A and E2 proteins, expressed from the replicon
and the packaging cell, respectively. Finally, virus production was
quantified by collecting the culture fluid of the co-cultured cells
48 h after fusion induction and by inoculation of highly permissive
Huh-7.5 cells and subsequent luciferase assays. In case of PBS-
treated co-cultured cells we did not observe cells simultaneously
expressing E2 and NS5A proteins indicating that this kind of
treatment did not induce formation of heterokaryons (Figure 2B).
Figure 1. HCV RNA replication and virus production in transfected human and mouse cell lines. (A) Different human and mouse cell lines
were transfected with Luc-Jc1 or a replication-deficient construct Luc-Jc1DGDD. HCV RNA replication was determined 4, 24, 48, 72 h post transfection
using luciferase assays and is expressed as relative light units. (B) In parallel, cell-free culture fluid of transfected cells was harvested 48 h post
transfection and infectivity was determined by inoculation of naı ¨ve Huh-7.5 cells with cell supernatants and subsequent luciferase assays at 72 h post
inoculation. Mean values of quadruplicate measurements of a representative experiment with 3 independent repetitions are shown. The grey
horizontal bar represents the background luciferase activity determined in mock infected Huh-7.5 cells.
doi:10.1371/journal.ppat.1002029.g001
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PLoS Pathogens | www.plospathogens.org 3 April 2011 | Volume 7 | Issue 4 | e1002029Figure 2. Trans-complementation of HCV assembly and release in heterokaryons between human liver cells. (A) Schematic overview of
the experimental procedure of PEG-mediated cell fusion. The JFH1 luciferase reporter replicon Luc-NS3-5B was transfected into naı ¨ve Huh-7.5 cells.
The next day cells were washed with PBS and co-cultured with naı ¨ve Huh-7.5 cells or Huh-7.5 packaging cells constitutively expressing core, E1, E2, p7
and NS2 (Huh-7.5[CE1][E2p7NS2]). After 24 h of incubation, fusion was induced by treating co-cultivated cells with 40% PEG for 5 min at 37uC.
Treatment with PBS instead of PEG served as control. After 48 h cell-free supernatant was used to inoculate naı ¨ve Huh-7.5 cells following
determination of infectivity by luciferase assay. (B) For the detection of cell fusion and heterokaryon formation, cells were immunostained using
monoclonal antibodies directed against structural protein E2 and non-structural protein NS5A. Simultaneous expression of both proteins within cells
is indicative of heterokaryon formation (compare white arrows). (C) Fusion of Huh-7.5 cells transfected with a subgenomic reporter replicon to either
Huh-7.5 naı ¨ve or Huh-7.5 packaging cells using PEG or PBS as a negative controls. Production of infectious particles was quantified by inoculation of
naı ¨ve Huh-7.5 cells followed by luciferase readout 72 h post-infection. Mean values of 4 independent experiments and the standard deviations of the
means are given. The grey horizontal bar represents the background luciferase activity determined in mock infected Huh-7.5 cells.
doi:10.1371/journal.ppat.1002029.g002
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readily detected cells expressing both E2 and NS5A proteins thus
indicating that cell fusion between the different cell types had
occurred. Importantly, cell fusion between these cells efficiently
restored virus production and resulted in transduction of luciferase
activity to naı ¨ve Huh-7.5 cells inoculated with culture fluids
collected from PEG-treated co-cultures of replicon and Huh-
7.5[CE1][E2p7NS2] packaging cells (Figure 2C). Notably, PBS
treatment of these co-cultures as well as PEG treatment of co-
cultures between replicon and naı ¨ve Huh-7.5 cells did not permit
transduction of luciferase activity. Together these results indicate
that the trans-complementation assay described above permits
rescue of HCV particle production in heterokaryons between
human liver cells in a cell fusion-dependent fashion.
Production of infectious HCV from heterokaryons
between human liver cell lines and human non-hepatic
or mouse liver cell lines
Next, we applied this system to investigate if packaging cell lines
from human non-hepatic or mouse liver cells would also rescue
HCV particle production when fused with Huh-7.5 replicon cells.
To this end we created several novel packaging cell lines by using
two lentiviral vectors transducing core, E1 and E2, p7, NS2
proteins, respectively [31] (Table S1). Transgene expression was
confirmed by western blot (data not shown) and by using a
commercial core specific ELISA as well as an E2-specific ELISA
for detection of representative proteins derived from the individual
vectors (Figure 3A and 3B and Figure S1). Core protein expression
was readily detected and was very similar between all individual
packaging cell lines (Figure 3A). Similarly, E2 protein expression
was well detectable (Figure 3B) with high E2 protein levels in
HeLa and 293T, intermediate amounts in Huh-7.5 and Hep56.1D
and comparatively low quantities in AML12, Hepa1-6 and HuH6
packaging cells. Importantly, after co-culture with Huh-7.5 cells
transfected with the luciferase replicon and induction of
heterokaryons by PEG all packaging cell lines tested efficiently
rescued production of infectious HCV particles as is evident from
transduction of high levels of luciferase activity to the inoculated
naı ¨ve Huh-7.5 cells (Figure 3C). Since neither PBS treatment of
these co-cultures, nor cell fusion between Huh-7.5 replicon cells
and the naı ¨ve non-liver or non-human cell lines permitted
transduction of luciferase, we concluded that virus production
required cell fusion and expression of viral proteins core, E1, E2,
p7 and NS2 in the packaging cell lines. Together, these data
indicate that infectious HCV particles are produced upon fusion
between human liver cells expressing a subgenomic HCV replicon
with various human non-liver cells or mouse liver cells providing
the remaining viral proteins in trans.
To firmly establish that infectious particles produced from these
heterokaryons enter Huh-7.5 target cells in the same way as
authentic HCV particles and that luciferase expression in the
inoculated cells resulted from genuine infection rather than non-
specific transfer of reporter gene activity, we investigated if the
released particles infect target cells in a CD81-dependent manner.
Huh-7.5 cells were inoculated with cell culture fluids harvested
from heterokaryon-cultures in the presence of CD81-specific
antibodies or control antibodies against CD13, an irrelevant
protein expressed on the surface of Huh-7.5 target cells. As
depicted in Figure 4, anti-CD81 antibodies reduced reporter
activity in inoculated cells by more than 80% to almost
background levels (Figure 4).
Taken together, these results show that formation of hetero-
karyons between Huh-7.5 replicon cells and human hepatic,
human non-hepatic and mouse hepatoma packaging cell lines
rescued virus production and that produced infectious particles
utilize CD81 during infection. Therefore, these data indicate that
HCV replication, assembly and release are not repressed in these
non-permissive cell lines in a dominant negative fashion.
Notably, the efficiency of virus production between heterokary-
ons was substantially different (Figure 3C). This could be due to
various reasons, including dissimilar expression levels of transgenes
(HCV core to NS2 proteins), fusion efficiency, and abundance of
replication co-factors or restriction factors. Regarding the latter,
kinetic and extent of response to pathogen associated molecular
patterns (PAMPs) and subsequent induction of antiviral mecha-
nisms may substantially influence virus production. Therefore, to
investigate why heterokaryons between human Huh-7.5 replicon
cells and mouse AML12 packaging cells produced more than 20-
fold lower infectious virus particles than heterokaryons between
Huh-7.5 replicon cells and human HuH6 packaging cells or mouse
Hep56.1D packaging cells (Figure 3C), we compared fusion
efficiency and responsiveness to viral PAMPs between these
packaging cell lines. The relative number of fused cells displaying
both replicon-expressed NS5A and at the same time E2 from the
lentiviral transduction was similar between these packaging cell
lines (Figure S2). Therefore, we can exclude that dissimilar fusion
was responsible for these marked differences in virus production.
Responsiveness of packaging cell lines to viral PAMPs was
measured by inoculation with a recombinant La Crosse virus
lacking the non-structural protein NSs (rLACVdelNSs;[32]).
Subsequently, mRNA levels of ISG56 and IFN-b were determined
by quantitative RT-PCR as a measure of antiviral signaling. As
expected, Huh-7.5 packaging cells which carry a defective RIG-I
protein [33], that is essential for detection of viral PAMPs, did not
upregulate ISG56 or IFN-b mRNA levels (Figure 5). Notably, also
HuH6 packaging cells responded poorly and only marginally up-
regulated ISG56 and IFN-bmRNA levels upon La Crosse virus
challenge. In contrast both mouse packaging cell lines strongly and
rapidly increased transcription of ISG56 and IFN-b thus
indicating that they efficiently detect viral PAMPs. Given that
Hep56.1D packaging cells fused with Huh-7.5 replicon cells
readily produce infectious particles despite of vigorous responsive-
ness to viral PAMPS, these findings exclude that rapid and
efficient recognition of viral PAMPs in mouse packaging cell lines
precludes production of infectious virus particles in the hetero-
karyons.
Both human and mouse IFN-a inhibit virus production in
human-mouse heterokaryons
HCV propagation in tissue culture is strongly inhibited by
interferon, albeit by as far incompletely defined anti-viral
mechanisms. To exclude that Hep56.1D packaging cells sustain
virus production due to the inability to respond to IFN, we used
mouse interferon alpha (IFN-a) to establish that these cells are not
refractory to IFN and that our cell fusion assay efficiently detects
dominant restriction factors – in this case IFN induced – that
prevent efficient HCV virus production. First we confirmed that
mouse IFN-a induces an antiviral state only in mouse cells and not
in human cells incubated with recombinant mouse IFN-a. Since
Hep56.1D cells cannot be infected with HCV, we chose an
interferon-sensitive vesicular stomatitis reporter virus (Luc-VSV)
which efficiently infects mouse cells to assess responsiveness of
these cells to mouse and human IFN-a. To evaluate sensitivity of
Huh-7.5 cells to IFNs of human or mouse origin we employed the
HCV reporter virus Luc-Jc1. Importantly, infection of Huh-7.5
cells by Luc-Jc1 was only inhibited by human IFN but not affected
by mouse IFN (Figure 6A). In turn infection of Hep56.1D cells by
Luc-VSV was only inhibited by mouse IFN but not by human IFN
Complete HCV Replication Cycle in Heterokaryons
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responsive to IFNs and that induction of the antiviral state by IFN
is species-specific in both cell lines. Next we explored if both mouse
and human IFN induce restriction factors in Huh-7.5 replicon or
Hep56.1D packaging cells which prevents virus production in
fused heterokaryons. To this end, Huh-7.5 replicon or Hep56.1D
packaging cells were pre-incubated with either human or mouse
IFN-a, subsequently these cells were co-cultured and fused by
PEG, before production of virus particles was measured by
transduction of luciferase activity to naive Huh-7.5 cells
(Figure 6C). In this context production of infectious HCV particles
was strongly repressed by both mouse and human IFN-a
suggesting that both mouse and human IFN-a induced antiviral
effector mechanisms that efficiently control HCV particle
production.
Finally, to explore the importance of the time point of IFN-
treatment for virus production in the heterokaryon fusion assay
between Hep56.1D packaging cells and Huh-7.5 replicon cells, we
applied mouse IFN-a for 4 h at different time points before co-
culture, during co-culture or after induction of cell fusion by PEG
Figure 3. Production of infectious HCV from heterokaryons between human liver cells and human non-hepatic or mouse liver cells.
(A) HCV packaging cell lines constitutively expressing core, E1, E2, p7 and NS2 were created using two lentiviral vectors expressing core, E1 and E2,
p7, NS2, respectively (Materials and Methods, and see also Table S1). Core protein expression in the individual packaging cell lines as determined by a
commercial core-specific ELISA. (B) Lysates of given packaging cell lines were normalized for equal total protein content, serially diluted and
incubated with Galanthus nivalis lectin coated culture plates to capture glycosylated proteins. Bound viral E2 protein was detected using an
E2-specific monoclonal antibody (AP33). In each case, lysates of the parental cell line served as negative control. The OD value was plotted against the
reciprocal dilution of the cell lysate. Relative expression of E2 protein between different cell lysates was determined by linear regression analysis as
described in Material and Methods. The reciprocal dilution of the cell lysate required to reach an OD value of 0.5 for each lysate is given. Raw data of
the ELISA are depicted in Figure S1. (C) Huh-7.5 cells transfected with the JFH1 replicon Luc-NS3-5B RNA were fused to the indicated naı ¨ve or
packaging cell lines using PEG. Forty eight hours later cell-free media of these cultures were collected and used to inoculate naı ¨ve Huh-7.5 cells. Viral
infectivity was quantified using luciferase assays. Mean values of 3 independent experiments and the standard deviations of the means are given. The
grey horizontal bar represents the background luciferase activity determined in mock infected Huh-7.5 cells. Note that in case of heterokaryons
involving AML12 and Hepa1-6 packaging cells, culture fluids were concentrated 20-fold to enhance sensitivity of the assay.
doi:10.1371/journal.ppat.1002029.g003
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tion with comparable efficiency irrespective of the time point of
addition arguing that the antiviral response induced via mouse
IFN-a is relatively sustained thus suppressing virus production at
least up to 80 h post treatment.
Completion of entire virus replication cycle in human-
mouse heterokaryons
It is well established that a high burden of viruses can saturate
and ultimately overcome endogenous host cell restrictions. To
exclude that a high viral load in transfected Huh-7.5 cells may
have precluded detection of restrictions present in human non-
liver or mouse liver cells simply by saturation of such factors, we
wished to confirm our findings using a second independent
approach based on HCV infection rather than transfection. To
this end we used a Huh-7-derived cell line designated Lunet N
which lacks endogenous CD81 expression [34]. As a consequence,
Lunet N cells cannot be infected by HCV unless human CD81 is
reintroduced [14]. When these cells are fused with cells expressing
human CD81 but not the complete set of viral entry factors, only
fused cells display all necessary entry factors thus rendering only
the heterokaryons susceptible. Following this rationale, we co-
cultured Lunet N cells either with 293T or HeLa cells which both
express human CD81 but which are non-permissive to HCV cell
entry due to lack of at least one essential HCV entry factor [10,35]
(Table S2). In parallel we fused Lunet N cells with naı ¨ve
Hep56.1D, AML12 or Hepa1-6 cells or derivates of these cell
lines expressing human CD81. Prior to co-cultivation, cell lines
were stained by two different fluorescent CellTrackers to allow
discrimination of cell types and detection of successful cell fusion
[36]. Formation of heterokaryons between cells was subsequently
induced by a transient transfection of a plasmid encoding a
fusogenic viral glycoprotein of the prototype foamy virus [37]
(Figure 7A). This method of cell fusion induction was chosen to
increase sensitivity of the assay due to increased fusion rates.
Fluorescence microscopy revealed that the expression of the highly
fusogenic glycoprotein led to the accumulation of syncytia stained
with both CellTrackers (Figure 7B). Thirty hours after transfection
of the fusogenic envelope protein into the co-cultured cells, the cell
population was inoculated with the HCV Jc1 chimera (MOI 2.3)
which grows to high virus titers in tissue culture [38]. Completion
of the viral replication cycle including productive entry, RNA
replication as well as assembly and release of infectious progeny
virus particles was measured by titration of cell free infectivity
Figure 4. Neutralization of virus particles released from heterokaryons by CD81- specific antibodies. Huh-7.5 cells were inoculated with
supernatants derived from heterokaryons between Luc-NS3-5B transfected Huh-7.5 cells and given packaging cell lines in the presence of CD81-
specific monoclonal antibodies or CD13 control antibodies. The efficiency of infection was determined 72 h later by luciferase reporter assay and is
expressed relative to infection in the presence of CD13-specific antibodies. Mean values of at least two independent experiments and standard
deviations of the means are displayed.
doi:10.1371/journal.ppat.1002029.g004
Figure 5. Responsiveness of selected packaging cell lines to viral pathogen associated molecular patterns. Given cell lines were
inoculated with a recombinant La Crosse virus lacking the non-structural protein NSs (rLACVdelNSs;[32]). At 8 or 16 h post inoculation (p.i.) cells were
collected and expression levels of IFN-b (left) and ISG56 (right) were determined by quantitative RT-PCR. The relative induction compared to cells that
were not inoculated with the virus is given. Mean values of three independent experiments including the standard deviations are given.
doi:10.1371/journal.ppat.1002029.g005
Complete HCV Replication Cycle in Heterokaryons
PLoS Pathogens | www.plospathogens.org 7 April 2011 | Volume 7 | Issue 4 | e1002029Figure 6. Effect of human and mouse IFN-a treatment on HCV and VSV in human and mouse cells as well as in human-mouse
heterokaryons. (A) Four hours prior to infection with Luc-Jc1, Huh-7.5 cells were treated with the indicated dose of human or mouse IFN-a. HCV
infectivity was assessed by measuring luciferase activity 72 h post-infection. (B) Hep56.1D cells were pre-incubated for 4 h with different doses of
human or mouse IFN-a following inoculation with Luc-VSV for 4 h. After 72 h infectivity was determined by luciferase assay. (C) Either Huh-7.5
replicon cells or Hep56.1D[CE1][E2p7NS2] packaging cells were incubated with human or mouse IFN-a for 4h before co-culture. Production of trans-
complemented particles after PEG-mediated induction of cell fusion was quantified by inoculation of naı ¨ve Huh-7.5 cells with cell supernatants of
these cultures and determination of luciferase activity 72 h later. Mean values of two independent experiments and standard deviations of the means
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residual infectivity of the inoculum or low numbers of directly
infected susceptible Lunet N cells are solely responsible for the
detection of infectious virus at this time point, we included Lunet
N cells fused with Lunet N cells as control. Importantly, in this
control we observed only very low levels of infectious HCV
ranging between 5 and 10 TCID50/mL which is close to the
detection limit of the limiting dilution assay. In contrast, when
Lunet N cells were fused with 293T cells and challenged with the
same viral inoculum, viral titers as high as 4610
3 were detected
providing strong evidence that in this case relatively high numbers
of progeny infectious particles had been produced (Figure 7C).
Similarly, when using HeLa cells for heterokaryon formation with
Lunet N cells, also substantial numbers of infectious particles were
produced, reaching levels approximately 10-fold higher than the
background infectivity observed with Lunet N cells. Importantly,
HCV inoculation of Lunet N cells fused with mouse liver cells
expressing human CD81 also resulted in production of well
detectable quantities of infectious HCV about 5- to 20-fold higher
than after fusion of naı ¨ve mouse liver cells with Lunet N cells
(Figure 7C). In conclusion these results indicate that fusion of
Lunet N cells with cells expressing human CD81 complements the
lacking surface receptor, thus allows HCV cell entry and de novo
production of infectious particles from the resulting heterokaryons.
Importantly, completion of the HCV replication cycle was
observed when human liver cells (Lunet N cells) were fused with
human non-liver cells (293T, HeLa) and three different mouse
liver cell lines. It is worth mentioning here that all three mouse
liver cell lines express functional viral pattern recognition
pathways as is evident from efficient induction of IFN-b and
ISG56 gene transcription as well as IFN secretion upon
stimulation with viral RNA, poly(I:C) or upon infection with a
Bunyavirus mutant (Figure S3). Together these findings provide
strong evidence that these cell types do not express dominant
restriction factors precluding HCV entry, RNA replication, virus
assembly and release and that the endogenous pattern recognition
pathways are insufficient to fully control HCV propagation.
Discussion
HCV is a highly tissue- and species-specific virus which
efficiently replicates only in human and chimpanzee liver cells.
Three principal mechanisms may prevent HCV from infecting
other species. These are lack of essential host cell factors, their
genetic incompatibility, or alternatively the expression of domi-
nant restriction factors. Previous reports have highlighted that
indeed inefficient usage of HCV entry factors from mouse origin
precludes infection of mouse cells [10,11,12,13]. Moreover,
ectopic expression of a liver-specific miRNA (miR-122) which is
important for efficient HCV RNA replication [39] has been shown
to facilitate HCV replication in human non-hepatic cell lines or
mouse fibroblasts [40,41]. Finally, it was noted that HCV cell
entry is inhibited by expression of a CD81-binding protein in non-
liver cells [26]. However, comprehensive studies investigating
dominant cellular restriction factors which may limit HCV
replication have been lacking.
In case of retroviruses, most notably HIV-1, it is well established
that host factors can potently repress completion of the retroviral
replication cycle: For instance pro-virus formation of HIV-1 is
impeded by APOBEC3G [23,42], TRIM5-a inhibits HIV-1 by
acting before reverse transcription [24], and tetherin prevents
release of virions from infected cells [25,43]. Notably, HIV-1
encodes viral factors like Vif and Vpu that efficiently suppress
these innate host cell defense mechanisms by inducing degradation
of APOBEC3G and tetherin, respectively [25,44,45]. Importantly,
viral interference with these factors is species-specific, since for
instance Vpu fails to protect HIV-1 from non-human tetherin
[45,46] and as HIV-1 Vif does not interfere with murine
APOBEC3G [47,48]. Consequently, the interaction of HIV-1
with restriction factors plays a key role in determining species
tropism (summarized in [49]). Notably, also the hepatitis B virus is
targeted by APOBEC3G [50] and tetherin prevents release of
diverse enveloped viruses from divergent virus families including
retroviruses, arenaviruses, filoviruses and herpesviruses
[51,52,53,54].
Given these circumstances we investigated if restriction factors
limit HCV propagation in non-permissive cell lines by using
somatic cell fusion between permissive and non-permissive cells.
Employing this approach we provide strong evidence that HCV
efficiently completes its replication cycle in heterokaryons between
human liver cells and human non-hepatic or mouse liver cell lines.
In turn, these results suggest that HCV propagation in these cell
types, and possibly also in primary human non-liver tissue or in
mouse liver, is not ablated by constitutive or virus-induced
expression of restriction factors. This conclusion is based on two
independent experimental systems employing in total five cell
lines. We ensured that virus production can only occur in true
heterokaryons between human liver cells and non-permissive cell
lines by choosing two different trans-complementation systems. On
one hand, virus production of a subgenomic HCV replicon
transfected into highly permissive Huh-7.5 cells was complement-
ed by fusion of these cells with packaging cells constitutively
expressing the lacking viral assembly factors. Alternatively, we took
advantage of a Huh-7-derived cell clone lacking endogenous
CD81 expression and fusion with cell lines expressing human
CD81. When challenged with HCV, only heterokaryons between
these cell types express all necessary factors rendering only these
permissive for viral entry.
Notably, in both systems productive complementation of the
viral replication cycle likely depends on a number of factors
including transgene expression, efficiency of cell fusion as well as
abundance of essential (in part unknown) viral co-factors and viral
restriction factors. In part these factors cannot be quantified;
therefore it is not possible to establish at this point why virus
production efficiency differs between heterokaryons. Notably, we
observed much lower virus production in heterokaryons between
Huh-7.5 replicon cells and AML12 packaging cells compared to
heterokaryons between Huh-7.5 replicon cells and HuH6, or
Hep56.1D packaging cells (Figure 3C). Since the fusion efficiency
was similar between these cells, we can exclude that this accounts
for these dissimilarities in virus production. Moreover, we can rule
out that efficient detection of viral PAMPs precludes virus
are displayed. (D) Mouse IFN-a was applied to Hep56.1D packaging cells for 4 h either at indicated time points before co-culture, or to cells co-
cultured with Huh-7.5 replicon cells as indicated by cross hatched boxes of the diagram displayed above. Alternatively, mIFN-a was present for 48 h
directly after fusion induction and until harvesting of cell culture fluid. In each case infectivity produced was determined by inoculation of naı ¨ve Huh-
7.5 cells and is expressed relative to the control which was not treated with mouse IFN-a. Mean values of quadruplicate measurements including the
standard deviations are shown. The grey horizontal bar indicates the background of the assay based on the luciferase activity determined in Huh-7.5
cells that had not been infected.
doi:10.1371/journal.ppat.1002029.g006
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Huh-7 Lunet N cells lacking CD81 (refractory to HCV cell entry; [34]) were co-cultured with the indicated cell lines lacking or expressing human CD81
(see also Table S2). Fusion between these cells was initiated by transfection of a fusogenic viral envelope protein derived from the prototype foamy
virus the next day. Thirty hours later, cells were challenged with infectious HCV particles. Cell entry, RNA replication and virus production sustained by
these cultures was quantified by determining infectivity titers in the cell-free culture fluid 48 h post inoculation using naı ¨ve Huh-7.5 cells as target
cells for a limiting dilution assay. (B) For the detection of heterokaryons formed due to expression of the prototype foamy virus envelope protein,
cells were stained with CellTracker Green or CellTracker Orange 6 h prior to co-cultivation (and transfection). Thirty hours later, cells were fixed with
3% PFA and stained with DAPI. The white arrow indicates heterokaryons produced upon co-culture of Lunet N cells labeled with CellTracker Orange
and Lunet N cells stained with CellTracker Green. (C) Huh-7 Lunet N cells were fused to the different naı ¨ve cell lines or cell lines transduced to express
human CD81. These cultures were inoculated with cell culture derived HCV particles (MOI of 2.3). Culture fluid was collected 48 h later and de novo
particle release from heterokaryons was determined by limiting dilution (TCID50) using naı ¨ve Huh-7.5 target cells. Mean values of 3 independent
experiments are given. The grey bar represents the detection limit of the limiting dilution assay.
doi:10.1371/journal.ppat.1002029.g007
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readily respond to viral triggers of antiviral signaling (Figure 5) but
nevertheless produce comparatively high levels of infectious
particles in the heterokaryon assay (Figure 3C). It is worth
mentioning though that virus production in heterokaryons
involving either Huh-7.5 packaging cells or HuH6 packaging cells
was consistently 3 to 4 fold more efficient than in those with
Hep56.1D packaging cells. Since Hep56.1D packaging cells
express at least as much viral transgenes and fuse similarly well
as the human liver Huh-7.5- and HuH6-derived packaging cells
this difference could be due to either lower abundance of
important viral cofactors in the mouse liver cell line or due to
partial control of virus production by cellular antiviral defenses in
Hep56.1D packaging cells. In any case, our data firmly exclude
that dominant restriction factors fully ablate HCV propagation in
these cell types. In turn, it is reasonable to assume that lack of
essential human co-factors is a primary limitation for efficient
HCV propagation in mouse cells. Such species-specific host factors
could for instance be identified by introduction of human cDNA
libraries into mouse cells and subsequent screening for those
cDNAs which confer increased HCV replication capacity to
mouse cells.
Our results also provide first evidence that virus-induced
antiviral programs in mouse cells may be insufficient to fully
control HCV infection and replication: It is unlikely that high viral
load, as present after transfection, simply overrides endogenous
antiviral pathways since we observed completion of the HCV
replication cycle not only upon fusion of HCV transfected cells
carrying a high dose of replication-competent viral RNA, but also
after infection with HCV. Second, we can exclude that the mouse
cells are unable to sense viral infection due to lesions in the
pathways triggering interferons since ligands of MDA5 [poly(I:C)]
and RIG-I (59triphosphorylated VSV RNA), as well as Bunyavirus
infection efficiently elicited ISG56 and IFN-b gene expression as
well as IFN secretion. Finally, we can also rule out that the cells
tested by us are non-responsive to IFN, since stimulation of
antiviral effectors in Hep56.1D mouse cells via mouse IFN-a
strongly inhibited Luc-VSV infection or HCV particle production
in mouse-human heterokaryons. Importantly, treatment of either
Huh-7.5 replicon cells with human IFN-a or likewise Hep56.1D
packaging cell lines with mouse IFN-a at different time points
prior to co-culture efficiently reduced virus production in the
heterokaryons (Figure 6). These results suggest that not only
human factors induced by human IFN but also mouse factors
stimulated by mouse IFN are able to control HCV particle
production. However, in the context of mouse-human hetero-
karyons these IFN-dependent antiviral effectors are either not
sufficiently activated by HCV or not capable to ablate production
of infectious particles upon HCV infection for instance due to
incompatibility of mouse antiviral effectors for control of HCV
infection/replication. Notably, HCV naturally induces cellular
innate immunity through RNA composition-dependent activation
of RIG-I [55,56] and subsequent signaling via IRF-3. However, at
least in human liver cells HCV interferes with RIG-I dependent
signaling to IRF-3 by NS3-4A-dependent cleavage of the crucial
adaptor protein Cardif [55]. Likewise, TLR-3 dependent signaling
to IRF-3 is ablated by cleavage of Trif through the viral NS3-4A
protease [57]. Since infection of mouse-human heterokaryons with
HCV particles apparently did not induce innate defenses to an
extent sufficient to control HCV propagation, we speculate that
HCV’s ability to interfere with the induction of innate immunity
may be sufficient to prevent adequate recognition and clearance of
virus also by mouse innate immune factors. In this regard it is
worth mentioning that Ahle ´n et al. recently reported that the
HCV NS3-4A protease is capable of cleaving mouse RIG-I which
may be an essential prerequisite for (partial) viral evasion of innate
immune control in mouse liver cells [58]. On the other hand, Lin
et al. observed that poor replication of HCV in murine embryonic
fibroblasts was facilitated by deletion of interferon regulatory
factor 3 (IRF-3) suggesting that IRF-3-dependent mechanisms
may partially restrict HCV replication in mouse cells [41]. Clearly
more work is needed to fully define the interplay between HCV
and mouse innate immunity and to appreciate by which extent it
contributes to low replication of HCV in these cells.
Despite successful development of cell culture systems to study
the complete HCV replication cycle [59,60,61], analysis of
mechanisms of virus pathogenesis and immune control as well as
vaccine development are severely hampered by the lack of
immunocompetent small animal models. The results presented
in this study provide strong evidence that dominant restriction
factors are unlikely to preclude propagation of HCV in mouse
liver cells. This raises the hope that permissive small animal
models could be developed without manipulation of innate,
intrinsic or adaptive immunity factors. Adaptation of HCV to
mouse cells or transgenic expressions of human viral co-factors are
promising approaches to ultimately establish urgently needed
small animal models for HCV.
Materials and Methods
Plasmids
The plasmids pFK-Jc1, pFK-Luc-Jc1, pFKi389Luc-EI/NS3-
39_JFH1_dg have been described earlier [28,31,38], The construct
Luc-Jc1DGDD has an in-frame deletion of 10 amino acids
(MLVCGDDLVV) encompassing the GDD motif of NS5B [62].
Lentiviral plasmids pWPI-CE1-BSD, pWPI-E2p7NS2-BSD have
been described previously [31]. pWPI-CE1-GUN was created by
restriction digest of pWPI-CE1-BSD with BamHI and SpeI and
transfer of the insert in the digested vector pWPI-GUN [14]. The
plasmids pczHFVenvEM066 and pWPIhCD81BLR have been
described previously [14,63]. Exact cloning strategies are available
on request. IFN reporter plasmid Mx1-Luc was described
elsewhere.
A recombinant, glycoprotein G gene-deleted VSV replicon
expressing firefly luciferase, VSV*DG(Luc) has been generated by
reverse genetics according to published protocols [64]. A detailed
characterization of this vector will be published elsewhere.
Cell culture
Huh-7.5, HuH6, 293T, HeLa, Hep56.1D, and Hepa1-6 cell
lines were maintained in Dulbecco’s modified Eagle medium
(DMEM; Invitrogen, Karlsruhe, Germany) supplemented with
2 mM L-glutamine, non-essential amino-acids, 100 U/mL peni-
cillin, 100 mg/mL streptomycin and 10% fetal calf serum (DMEM
complete). AML12 cells were maintained in DMEM/Ham’s F-12
medium supplemented with 10% FCS, 40 ng/mL dexametha-
sone, 5 mg/mL insulin, 5 mg/mL transferrin, 5 ng/mL selenium,
100 U/mL penicillin and 100 mg/mL streptomycin as described
before [65].
Cell lines expressing viral proteins C, E1, and E2, p7, and NS2
from two independent genetic cassettes were created by lentiviral
gene transfer as described previously [31]. Lentiviral particles were
produced using the plasmids pCMV-DR8.74 [66], pcz-VSV-G
[67], and derivatives of pWPI, (encoding the genes of interest and
in addition either the blasticidin S deaminase of Aspergillus terreus or
a GFP-ubiquitin-neomycin fusion protein (GUN), conferring
resistance against blasticidin or G418, respectively [14]. Parental
cell lines were transduced and selected in the presence of either
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5 mg/mL), or together with geneticin (G418; 750 mg/mL, Life
Technologies), as indicated in Table S1. Expression of viral
proteins was confirmed by Western blot analysis using a-E2
(AP33), a-core (C7-50) and a-mouse-peroxidase antibodies as
reported elsewhere [31]. Murine cell lines expressing human
CD81 were created by lentiviral gene transfer as described above
using a pWPI derivative [14] and selected using blasticidin.
Expression of CD81 was confirmed by FACS analysis using a-
CD81 (1.3.3.22, Ancell) and goat a-mouse antibody conjugated to
APC (eBioscience, data not shown).
HCV replication and infection assays
HCV particles and firefly luciferase HCV reporter viruses were
generated as reported previously [28]. In brief, plasmid DNA was
linearized and transcribed into RNA, which was then electropo-
rated into Huh-7.5 cells. Virus-containing culture fluids of
transfected cells were harvested 48 h and 72 h after transfection.
Luciferase reporter virus infection assays were carried out and
analyzed as described [28]. Wildtype HCV particles were titrated
by using a limiting dilution assay [31]. The 50% tissue culture
infectious dose (TCID50) was calculated based on the methods
described by Spearman and Ka ¨rber [68,69].
Polyethylene glycol-mediated fusion and infectivity assay
Formation of heterokaryons between permissive and non-
permissive cell lines was induced by PEG. In detail, 10 mg in-
vitro RNA transcript of the luciferase reporter HCV replicon Luc-
NS3-5B was transfected into naı ¨ve Huh-7.5 cells (6610
6 cells) by
electroporation; the cells were resuspended in 10 mL DMEM and
seeded onto a 10 cm dish. The next day cells were washed with
PBS and 5610
5 cells were co-cultured with 5610
5 Huh-7.5 naı ¨ve
or packaging cells (cell numbers adjusted to growth efficiency) on a
6-well culture plate. After 24 h of incubation, at a cell density of
,80%, fusion was induced by treating co-cultivated cells with
40% PEG-1500 in PBS (Roche, Mannheim, Germany) or PBS as
a control for 5 min at 37uC, followed by extensive washing,
addition of 2 mL DMEM/well and 48 h of incubation. Produc-
tion of infectious trans-complemented particles was determined as
described [31]. In case of heterokaryons formed with AML12 and
Hepa1-6 naı ¨ve and the respective packaging cells, assay sensitivity
was enhanced by concentration of the supernatants from 6-well
plates by 20-fold using Amicon ultrafiltration devices (Millipore)
according to the manufacturer’s protocol.
Induction of antiviral responses by Interferon treatment
To test if IFN-a treatment induces cellular restrictions, Huh-7.5
replicon and Hep56.1D packaging cells were pre-incubated with
either human IFN-a-2b (0–100 U/mL, IntronA, Essex Pharma,
Mu ¨nchen, Germany) or mouse IFN-a-1 (0–100 U/mL, PBL
InterferonSource, Piscataway, USA) for 4 h prior to co-cultivation.
For the time kinetic Hep56.1D packaging cells were pre-incubated
with mouse IFN-a-1 (100 U/mL) at indicated time points prior to
co-cultivation, 4 h prior to PEG-mediated cell fusion, or 4 h post
fusion.
Fluorescence microscopy
Staining of NS5A was performed by using the 9E10 hybridoma
supernatant [59] at a dilution of 1:2000. Immunostaining of E2
was performed using an E2-specific human monoclonal antibody
CBH-23 (kindly provided by Steven Foung, unpublished) at a
dilution of 1:250 in PBS supplemented with 5% normal goat
serum. After three times washing with PBS, bound primary
antibodies were visualized using goat anti-human or goat anti-
mouse IgG–specific secondary antibodies conjugated to Alexa
Fluor 488 or Alexa Fluor 546 (Invitrogen, Karlsruhe, Germany) at
a dilution of 1:1,000. DNA was stained with DAPI (49,69-
diamidino-2-phenylindole dihydrochloride; Invitrogen) for 1 min.
Finally, cells were washed three times with PBS, once with water
and mounted on glass slides with Fluoromount G (Southern
Biotechnology Associates, Birmingham, USA).
Staining of cells using CellTracker (CellTracker Green
CMFDA, Cell Tracker Orange CMTMR, Invitrogen) was
performed as recommended by the manufacturer. Briefly, cells
were incubated with 5 mMo r1 0mM of CellTracker Green or
Orange, respectively in serum-free media. Medium was changed
after 45 minutes and cells were incubated in standard DMEM
complete medium for 6 hours.
Determination of core and E2 expression
Viral transgene expression of the two lentiviral vectors encoding
HCV core, E1 and E2, p7, NS2, respectively was determined by
quantitative measurement of core and E2 proteins by enzyme-
linked immunoassay (ELISA). Packaging cells (4.5610
6) were lysed
in 1.5 mL of PBS supplemented with 1% Triton X-100 and core
protein abundance was determined using the ARCHITECT HCV
Core AG Test (Abbott, Wiesbaden, Germany) according to the
instructions of the manufacturer. For detection of HCV E2,
packaging cells (4.5610
6) were lysed in 1.5 mL Ripa buffer (0.3 M
NaCl, 20 mM Tris-HCl (pH 8), 1% sodium desoxycholate, 0.1%
sodium dodecyl sulphate, 1% Triton X-100 and protease
inhibitors (Roche, Mannheim). Total protein content of cell
lysates was determined by a standard Bradford assay. Subse-
quently equal quantities of cell lysates were analyzed as described
elsewhere [70]. In brief, Maxisorb mircrotiter plates (Nunc,
Langenselbold, Germany) were coated with 500 ng/well Galanthus
nivalis (GNA, Sigma-Aldrich, Steinheim, Germany) and blocked in
blocking buffer consisting of 2.5% non-fat dry milk, 2.5% normal
goat serum, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.1%
Tween-20. Cell lysates were bound on the GNA coated plates
prior to incubation with the primary antibody (AP-33 [71]) at
concentrations of 10 mg/well. After extensive washing with TBST
(20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween-20)
the bound primary antibodies were detected using an AP-
conjugated secondary antibody and 4-nitrophenyl phosphate
disodium salt hexahydrate (Sigma-Aldrich, Steinheim, Germany).
Absorbance was measured at 405 nm and 570 nm using a BioTek
Synergy 2 plate reader (BioTek, Winooski, Vermont, USA) and
the Gen5 1.08 software (BioTek).
To directly compare E2 expression between individual
packaging cell lines, we performed a linear regression analysis of
the relation between the Log OD value and the Log of the
reciprocal dilution of the cell lysate. Based on this analysis we
calculated the reciprocal dilution of the cell lysate required for an
OD value of 0.5 in the ELISA assay, which reflects the relative
expression of E2 between the given cell lysates.
CD81-mediated neutralization of HCV infection
Infectivity of HCV particles produced from heterokaryons was
inhibited with monoclonal antibodies against CD81. Huh-7.5 cells
were pre-incubated with either a-CD81 specific antibodies (JS-81,
Becton-Dickinson, Heidelberg, Germany) or a-CD13 antibodies
(Becton-Dickinson, Heidelberg, Germany) as a negative control at
a concentration of 5 mg/mL in DMEM for 30 min prior to
infection as previously described [28]. Luciferase activity was
determined 72 h post inoculation as described above.
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Huh-7.5 cells or Hep56.1D cells were seeded onto a 12-well
plate. The next day cells were pre-incubated with either
recombinant human (0–100 U/mL, hIFN-a-2b, IntronA, Essex
Pharma, Mu ¨nchen, Germany) or mouse IFN-a (0–100 U/mL,
mIFN-a-1, PBL Interferon Source, Piscataway, USA) for 4 h prior
to infection with Luc-Jc1 or Luc-VSV, respectively. Four hours
later medium was changed and IFN-a treatment resumed.
Replication was determined 72 h post-infection by analyzing
luciferase reporter activity in infected cells as described above.
Heterokaryon formation induced by foamy virus
glycoprotein expression and virus titration
Huh-7 Lunet N cells lacking CD81 [34] were co-cultured with
the indicated naive cell lines or the transduced cell lines expressing
human CD81 at a cell density of 1.5610
5 cells in a 12-well culture
plate. The ratio of the different cell lines to Huh-7 Lunet N cells was
adjusted according to the respective growth efficiency and ranged
between 1:1 and 1:2. Fusion between these cells was initiated the
next day by transfection of the co-cultures with a highly fusogenic
variant of the prototype foamy virus envelope protein pczHFVen-
vEM066 [63] using lipofectamine 2000 (Invitrogen). Cells were
challenged 30 hours later with infectious HCV particles produced
in cell culture at a multiplicity of infection (MOI) of 2.3. To remove
any unbound HCV particles left from inoculation, cells were
washed with PBS 12 hours after inoculation. Cell entry, RNA
replication and virus production was quantified by determining
infectivitytiters(TCID50/mL) inthe culture fluidsofthese cells48 h
post inoculation as described above.
Assessment of functional viral pattern recognition
pathways in mouse liver cells
Given mouse liver cell lines were mock treated or transfected with
500 ng 59triphosphorylated genomic RNA of VSV or with 10 mg
poly(I:C) per well of a 6-well plate using Metafectene (Biontex,
Martinsried, Germany) according to the instructions of the
manufacturer. Alternatively, cells were challenged with recombinant
La Crosse virus lacking the non-structural protein NSs (rLACV-
delNSs;[32]) at a MOI equal to 5. Cells were incubated for 16 h at
37uC and harvested. Total cellular RNA was extracted using the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the
instruction of the manufacturer. Transcript levels of mouse ISG56
and IFN-b were analyzed using the QuantiTect SYBR Green PCR
Kit in combination with QuantiTect Primer Assay (Qiagen) and the
following primers: Qiagen Mm_Ifit1_1_SG = QT01161286 (mouse
ISG56), Qiagen Mm_Ifnb1_1_SG = GT00249662 (mouse IFN-b).
In total 100 ng of cDNA was used for real time PCR in a final
reaction volume of 25 mL using an initial 15 minute denaturation at
95uC and 40 cycles consisting of 15 seconds denaturation at 94uC, 30
seconds annealing at 55uC and 30 seconds extension at 72uC. Signals
of inducible mRNAs were normalized to the GAPDH mRNA
(mouse GAPDH: Qiagen Mm_Gapdh_3_SG = GT01658692)
using the DDCt method [72]. Values of mock treated cells were set to
1. Secretion of IFN was monitored using a luciferase-based reporter
gene assay. Briefly, supernatants were treated with benzonase for 2 h
at 37uC to destroy inducer RNA. Alternatively supernatant was
incubated with b-propiolactone (Acros Organics, Geel, Belgium) at
4uC over night followed by 2 h at 37uC for inactivation of the
rLACdelNSs inducer virus. These inducer-cleared supernatants were
incubated for 16 h with murine embryonic fibroblasts that had been
transfected with 250 ng Mx1-Luc [73] and 25 ng pRL SV40
(Promega, Mannheim,Germany) reporter plasmids using Nanofectin
(PAA, Co ¨lbe, Germany). Cells were lysed and luciferase activity was
determined using the Promega Dual Luciferase assay according to
the instruction of the manufacturer. Recombinant, pan-specific IFN-
a (IFN-a B/D BgIII, PBL Biomedical Laboratories, Piscataway,
USA) served as standard.
Supporting Information
Figure S1 Quantification of E2 expression in packaging cell
lines. Lysates of given packaging cell lines were normalized for
equal total protein content, serially diluted and incubated with
galanthus nivalis lectin coated culture plates to capture glycosylated
proteins. Bound viral E2 protein was detected using an E2-specific
monoclonal antibody (AP33). In each case, lysates of the parental
cell line served as negative control. The OD value was plotted
against the reciprocal dilution of the cell lysate.
(TIF)
Figure S2 Comparable cell to cell fusion of different packaging
cell lines. Indicated packaging cell lines were co-cultured with
Huh-7.5 replicon cells. Fusion between co-cultured cells was
induced by PEG-treatment. Fusion efficiency was quantified by
counting the number of cells expressing both NS5A (replicon-
derived) and E2 (lentiviral expression) per total number of cells. In
total five independent microscopic views were evaluated including
at least 1,000 cells. Fusion efficiency is given as % of cells
displaying NS5A and E2 among the total cell population. Mean
values including the standard deviation is given.
(TIF)
Figure S3 Efficient induction of IFN-b and ISG56 gene
expression as well as IFN secretion in mouse liver cells by viral
pathogen associated molecular patterns. Given mouse cells were
either transfected with 59triphosphorylated VSV RNA, poly(I:C)
or infected with a recombinant La Crosse virus lacking the
nonstructural protein NSs (LACVdelNSs;[32]). Sixteen hours
later, cells and culture fluids were collected and (A) IFN-b and (B)
ISG56 gene expression were assessed by quantitative reverse
transcriptase polymerase chain reaction. (C) IFN secretion was
determined using a luciferase-based reporter assay as described in
the experimental procedures. Mean values of three independent
experiments including the standard deviations are given.
(TIF)
Table S1 Overview of packaging cell lines used in this study.
(DOC)
Table S2 Overview of origin and receptor expression of cell lines
used in this study. h: human; m: mouse, SR-BI: scavenger receptor
class B type 1, CLDN1: claudin-1, OCLN: occludin.
(DOC)
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